tradingkey.logo

Alvotech SA

ALVO
5.260USD
-0.030-0.57%
Close 12/26, 16:00ETQuotes delayed by 15 min
1.64BMarket Cap
22.42P/E TTM

Alvotech SA

5.260
-0.030-0.57%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Alvotech SA

Currency: USD Updated: 2025-12-26

Key Insights

Alvotech SA's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 106/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.75.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alvotech SA's Score

Industry at a Glance

Industry Ranking
106 / 404
Overall Ranking
221 / 4563
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Buy
Current Rating
8.750
Target Price
+60.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alvotech SA Highlights

StrengthsRisks
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 478.68% year-on-year.
Overvalued
The company’s latest PE is 22.42, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 18.18M shares, increasing 0.63% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 46.58K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.47.

Financial Health

Currency: USD Updated: 2025-12-26

The current financial score of Alvotech SA is 8.21, ranking 57/404 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 113.86M, representing a year-over-year increase of 10.56%, while its net profit experienced a year-over-year increase of 53.90%.

Score

Industry at a Glance

Previous score
8.21
Change
0

Financials

4.11

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

9.43

Shareholder Returns

7.49

Alvotech SA's Company Valuation

Currency: USD Updated: 2025-12-26

The current valuation score of Alvotech SA is 5.62, ranking 386/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is 22.42, which is 81.59% below the recent high of 40.72 and 169.68% above the recent low of -15.62.

Score

Industry at a Glance

Previous score
5.62
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 106/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-26

The current earnings forecast score of Alvotech SA is 8.00, ranking 168/404 in the Biotechnology & Medical Research industry. The average price target for Alvotech SA is 9.75, with a high of 10.00 and a low of 5.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
8.750
Target Price
+60.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Alvotech SA
ALVO
6
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-26

The current price momentum score of Alvotech SA is 7.24, ranking 124/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.97 and the support level at 4.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.27
Change
-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.111
Neutral
RSI(14)
48.212
Neutral
STOCH(KDJ)(9,3,3)
48.586
Buy
ATR(14)
0.337
Low Volatility
CCI(14)
3.799
Neutral
Williams %R
50.000
Neutral
TRIX(12,20)
-0.440
Sell
StochRSI(14)
94.733
Overbought
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
5.040
Buy
MA10
5.094
Buy
MA20
5.148
Buy
MA50
5.930
Sell
MA100
7.112
Sell
MA200
8.304
Sell

Institutional Confidence

Currency: USD Updated: 2025-12-26

The current institutional shareholding score of Alvotech SA is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 6.93%, representing a quarter-over-quarter decrease of 3.78%. The largest institutional shareholder is The Vanguard, holding a total of 4.35M shares, representing 1.39% of shares outstanding, with 0.42% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Aztiq Pharma Partners SARL
101.15M
-2.49%
Celtic Holdings SCA
90.01M
--
The Vanguard Group, Inc.
Star Investors
4.23M
+0.99%
Bracebridge Capital, LLC
2.71M
--
Oaktree Capital Management, L.P.
Star Investors
1.64M
-16.92%
T. Rowe Price International Ltd
1.39M
-0.82%
Littlejohn & Co. LLC
1.32M
--
Stefnir hf.
963.47K
-1.03%
Davies (Richard John)
1.07M
+1.88%
PointState Capital LP
1.05M
-10.67%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-26

The current risk assessment score of Alvotech SA is 3.77, ranking 133/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.77
Change
0
Beta vs S&P 500 index
0.11
VaR
+4.32%
240-Day Maximum Drawdown
+65.57%
240-Day Volatility
+63.05%

Return

Best Daily Return
60 days
+12.85%
120 days
+12.85%
5 years
+19.30%
Worst Daily Return
60 days
-34.25%
120 days
-34.25%
5 years
-34.25%
Sharpe Ratio
60 days
-1.40
120 days
-1.06
5 years
+0.00

Risk Assessment

Maximum Drawdown
240 days
+65.57%
3 years
+73.36%
5 years
+73.36%
Return-to-Drawdown Ratio
240 days
-0.92
3 years
-0.27
5 years
-0.13
Skewness
240 days
-1.47
3 years
-1.11
5 years
-0.53

Volatility

Realised Volatility
240 days
+63.05%
5 years
+62.12%
Standardised True Range
240 days
+7.68%
5 years
+7.03%
Downside Risk-Adjusted Return
120 days
-118.70%
240 days
-118.70%
Maximum Daily Upside Volatility
60 days
+71.61%
Maximum Daily Downside Volatility
60 days
+85.88%

Liquidity

Average Turnover Rate
60 days
+0.11%
120 days
+0.09%
5 years
--
Turnover Deviation
20 days
+146.66%
60 days
+78.28%
120 days
+37.03%

Peer Comparison

Biotechnology & Medical Research
Alvotech SA
Alvotech SA
ALVO
6.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
Charles River Laboratories International Inc
CRL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Alvotech SA?

The TradingKey Stock Score provides a comprehensive assessment of Alvotech SA based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Alvotech SA’s performance and outlook.

How do we generate the financial health score of Alvotech SA?

To generate the financial health score of Alvotech SA, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Alvotech SA's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Alvotech SA.

How do we generate the company valuation score of Alvotech SA?

To generate the company valuation score of Alvotech SA, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Alvotech SA’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Alvotech SA’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Alvotech SA.

How do we generate the earnings forecast score of Alvotech SA?

To calculate the earnings forecast score of Alvotech SA, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Alvotech SA’s future.

How do we generate the price momentum score of Alvotech SA?

When generating the price momentum score for Alvotech SA, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Alvotech SA’s prices. A higher score indicates a more stable short-term price trend for Alvotech SA.

How do we generate the institutional confidence score of Alvotech SA?

To generate the institutional confidence score of Alvotech SA, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Alvotech SA’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Alvotech SA.

How do we generate the risk management score of Alvotech SA?

To assess the risk management score of Alvotech SA, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Alvotech SA’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Alvotech SA.
KeyAI